Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance

Bristol Myers Squibb (NYSE:BMY) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.750-7.000 for the period, compared to the consensus earnings per share estimate of 6.310. The company issued revenue guidance of $49.0 billion-$50.0 billion, compared to the consensus revenue estimate of $47.3 billion.

Bristol Myers Squibb Stock Performance

BMY stock opened at $63.24 on Thursday. The stock’s 50 day simple moving average is $57.79 and its 200 day simple moving average is $58.22. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $64.96. The stock has a market capitalization of $129.14 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts forecast that Bristol Myers Squibb will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Analyst Ratings Changes

A number of research firms have issued reports on BMY. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Guggenheim reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus price target of $61.25.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Raised 2026 outlook: Bristol Myers lifted its full-year EPS guidance to $6.75–$7.00, above the $6.31 analyst consensus, and projected revenue of $49 billion–$50 billion, versus the $47.3 billion consensus. Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
• Positive Sentiment: Quarterly earnings beat expectations: The biopharmaceutical company reported adjusted EPS of $2.04, exceeding the $1.60 consensus estimate by $0.44. Profit and revenue benefited from strong demand for blood thinner Eliquis and newer products including Camzyos and Reblozyl. Bristol Myers Lifts Outlook as Profit, Revenue Rise
• Positive Sentiment: Newer medicines are gaining importance: Products such as Opdivo and other recently launched treatments are helping offset pressure from Bristol Myers’ older portfolio. Analysts, including Piper Sandler, remain constructive on BMY, while investor attention is also focused on artificial-intelligence drug-discovery opportunities and the company’s dividend-oriented valuation.
• Neutral Sentiment: Pipeline developments remain a watch point: A biotech partner is seeking regulatory approval for a product to be used with BMS’s cancer drug Opdivo. Approval could expand Opdivo’s commercial opportunity, but the regulatory process introduces uncertainty. Replimune Is Locked in a Standoff With Regulators
• Negative Sentiment: Legacy-drug declines remain a risk: Bristol Myers continues to face falling revenue from parts of its mature portfolio and future patent expirations. Investors will therefore assess whether newer products can sustain growth as Eliquis and other established medicines face longer-term competitive pressure. Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly Beat

Institutional Investors Weigh In On Bristol Myers Squibb

Several institutional investors have recently modified their holdings of BMY. Sunbelt Securities Inc. increased its position in Bristol Myers Squibb by 7.1% during the fourth quarter. Sunbelt Securities Inc. now owns 13,313 shares of the biopharmaceutical company’s stock valued at $718,000 after acquiring an additional 878 shares during the last quarter. Compound Planning Inc. lifted its holdings in shares of Bristol Myers Squibb by 104.4% in the 4th quarter. Compound Planning Inc. now owns 23,633 shares of the biopharmaceutical company’s stock worth $1,275,000 after acquiring an additional 12,072 shares during the last quarter. TMB Capital Partners LLC purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $356,000. Axxcess Wealth Management LLC boosted its stake in shares of Bristol Myers Squibb by 3.2% during the 4th quarter. Axxcess Wealth Management LLC now owns 79,944 shares of the biopharmaceutical company’s stock worth $4,312,000 after purchasing an additional 2,475 shares during the period. Finally, Birchwood Financial Partners Inc. bought a new position in Bristol Myers Squibb during the 4th quarter valued at about $50,000. 76.41% of the stock is owned by institutional investors.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.